Use of IL-2 receptor-targeted therapeutics to inhibit allograft rejection and treat autoimmune disorders
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 5, 2000
Issued Date -
N/A
app pub date -
Nov 21, 1997
filing date -
Sep 5, 1985
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Methods of inhibiting allograft rejection and of inhibiting B lymphocyte-mediated autoimmune diseases are provided. The methods involve the use of agents specific for the IL-2 receptor, such as monoclonal antibodies or IL-2, optionally linked to a cytotoxin. Administration of the agents inhibits the proliferation of lymphocytes expressing the IL-2 receptor and thus mitigates unwanted immune responses.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully